With 4.29 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.32 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $24.69 whereas the lowest price it dropped to was $20.609. The 52-week range on SEPN shows that it touched its highest point at $27.47 and its lowest point at $18.62 during that stretch. It currently has a 1-year price target of $43.67.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SEPN was up-trending over the past week, with a rise of 8.44%, but this was up by 7.91% over a month.
Float and Shares Shorts:
At present, 44.40 million SEPN shares are outstanding with a float of 31.06 million shares on hand for trading. In addition to Dr. Jeffrey T. Finer M.D., Ph.D. as the firm’s Co-Founder, CEO, President & Director, Ms. Elizabeth P. Bhatt M.B.A., M.S. serves as its Chief Operating Officer.
Institutional Ownership:
Through their ownership of 0.56569 of SEPN’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, SEPN reported revenue of $176000.0 and operating income of -$22550000.0. The EBITDA in the recently reported quarter was -$22186000.0 and diluted EPS was -$0.48861.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With SEPN analysts setting a high price target of 50.0 and a low target of 38.0, the average target price over the next 12 months is 43.66667. Based on these targets, SEPN could surge 105.93% to reach the target high and rise by 56.51% to reach the target low. Reaching the average price target will result in a growth of 79.85% from current levels.
Based on analyst estimates, the high estimate for the next quarter is -$0.52 and the low estimate is -$0.66. The average estimate for the next quarter is thus -$0.59.
